Core Insights - Hims & Hers Health, Inc. has made significant progress in international expansion, highlighted by the acquisition of ZAVA, a European digital health platform, which provides access to over 1.3 million active customers and nearly 2.3 million consultations in 2024 [1][7] - The company plans to enter the Canadian market, offering a low-cost weight loss program coinciding with the global launch of generic semaglutide, targeting the obesity treatment market [2][7] - Hims & Hers is transitioning from a U.S.-centric platform to a global digital health leader through strategic acquisitions and localized care delivery [3][7] Financial Performance - Hims & Hers shares have increased by 96.8% year to date, outperforming the industry growth of 6.2% [6] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share indicates a 177.8% improvement from 2024 [8] Valuation Metrics - Hims & Hers has a forward 12-month price-to-sales (P/S) ratio of 4.1X, which is lower than the industry's average of 5.5X but higher than its three-year median of 2.3X [10] - The company currently holds a Zacks Rank 1 (Strong Buy) [12]